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Abstract
Background: p53 is commonly inactivated by mutations in the DNA-binding domain in a wide range of cancers. As mutant p53
often influences response to therapy, effective and rapid methods to scan for mutations in TP53 are likely to be of clinical value.
We therefore evaluated the use of high resolution melting (HRM) as a rapid mutation scanning tool for TP53 in tumour samples.
Methods: We designed PCR amplicons for HRM mutation scanning of TP53 exons 5 to 8 and tested them with DNA from cell
lines hemizygous or homozygous for known mutations. We assessed the sensitivity of each PCR amplicon using dilutions of cell
line DNA in normal wild-type DNA. We then performed a blinded assessment on ovarian tumour DNA samples that had been
previously sequenced for mutations in TP53 to assess the sensitivity and positive predictive value of the HRM technique. We
also performed HRM analysis on breast tumour DNA samples with unknown TP53 mutation status.
Results: One cell line mutation was not readily observed when exon 5 was amplified. As exon 5 contained multiple melting
domains, we divided the exon into two amplicons for further screening. Sequence changes were also introduced into some of
the primers to improve the melting characteristics of the amplicon. Aberrant HRM curves indicative of TP53 mutations were
observed for each of the samples in the ovarian tumour DNA panel. Comparison of the HRM results with the sequencing results
revealed that each mutation was detected by HRM in the correct exon. For the breast tumour panel, we detected seven
aberrant melt profiles by HRM and subsequent sequencing confirmed the presence of these and no other mutations in the
predicted exons.
Conclusion: HRM is an effective technique for simple and rapid scanning of TP53 mutations that can markedly reduce the
amount of sequencing required in mutational studies of TP53.
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p53 is a tumour suppressor that plays a major role in reg-
ulating the cellular response to environmental and geno-
toxic stress, through cell cycle inhibition and promotion
of programmed cell death or senescence [1-4]. There are a
variety of stresses that have been shown to activate p53
including DNA damage, cell-cycle aberrations, hypoxia,
and aberrant growth signals resulting from expression of
oncogenes [5-10]. Moreover, a wide body of work has
established the role of p53 in response to DNA damage
[5-8].
It has been estimated that the gene encoding p53 (TP53)
is mutated in more than 50% of human cancers [9]. It
appears that inactivation of p53, by mutation or by other
means, is highly advantageous and perhaps an absolute
requirement for cancer progression (reviewed in Soussi,
2007). The prevalence of p53 mutations is highest in ovar-
ian cancer (48.3%), followed by colorectal cancer
(43.6%), oesophageal cancer (42.6%), head and neck
cancer (41.5%), and lung cancer (38.4%) [10].
In ovarian cancer, mutation of the TP53 gene appears to
play an important role in serous carcinogenesis, where
TP53 mutations are present in approximately 50% of
high-grade serous carcinomas but rare in serous border-
line tumours and low-grade serous carcinoma [11,12].
Mutations in TP53 are also common in ovarian and breast
tumours that are BRCA1-related [13,14].
Mutations can occur throughout TP53. However there are
also "hot spots" that account for many mutations [10,15].
In the majority of cancers, p53 dysfunction is caused
through a direct mutation within the DNA-binding
domain of the gene [9]. Moreover mutations in exons 5 to
8 of TP53 comprise 94.2% of all somatic mutations in the
IARC database, version R11 [10].
Different TP53 mutations appear to have different conse-
quences [16-18]. Work on the common p53 mutants,
R273H and R175H, using knock-in in vivo mice models
showed that each mutation was responsible for distinct
tumour patterns and characteristics, compared to mice
with complete loss of one p53 allele [19,20]. These studies
demonstrate that p53 mutant alleles may have an onco-
genic potential beyond the simple loss of p53 function.
This is also borne out by clinical studies in human cancer
where certain types of TP53 mutations are associated with
a poorer prognosis compared to other types of mutations.
For example, studies have shown that TP53 mutations
affecting the zinc binding domains or missense mutations
in the DNA binding domain correlate with poorer prog-
nosis in breast cancer [16,21].
Overabundance of p53 by immunohistochemistry has
been commonly used as a surrogate marker for TP53
mutation in a wide range of cancers and although the
method is cost effective, it does not have the required sen-
sitivity to predict TP53 mutations [12,22]. Dideoxy
sequencing remains the gold standard method to detect
these mutations. However, it has the disadvantages of
high cost in terms of labour and reagents. Sequencing is
used most effectively as a confirmatory method after pre-
screening with a mutation scanning technique for samples
that ideally have had enrichment of the tumour compo-
nent before DNA extraction.
High resolution melting (HRM) is a mutation scanning
technique that monitors the progressive change in fluores-
cence caused by the release of an intercalating DNA dye
from a DNA duplex as it is denatured by marginal
increases in temperature [23]. It is an in-tube method
requiring the inclusion of an saturating intercalating dye
in the PCR mix and the addition of a high resolution melt
step after PCR. The technique has already been employed
to scan for somatic mutations in the KIT, BRAF, EGFR,
ERBB2, and KRAS genes [24-27]. In this study, we show
that high resolution melting is a highly effective scanning
technique for mutations in TP53.
Methods
Study samples
Ovarian tumour samples were obtained from the West-
mead Gynaecological Oncology Tissue Bank (WGOTB)
and the Australian Ovarian Cancer Study (AOCS) [28], a
multi-centre study established to recruit women with a
suspected diagnosis of primary epithelial ovarian cancer,
including peritoneal and fallopian tube cancers, from
across Australia. Collection of clinical data and biological
materials was subject to informed consent by the patient.
Tissue collection (WGOTB) was approved by the Western
Sydney Area Health Service Human Research Ethics Com-
mittee. Tissue collection (AOCS) was approved by the
appropriate Ethics of Human Research Committees at the
Peter MacCallum Cancer Centre, Queensland Institute of
Medical Research, University of Melbourne and all partic-
ipating hospitals. An experienced pathologist reviewed
each sample. Tumour cells were enriched by needle-dis-
section of serial frozen tissue sections with reference to the
flanking H&E stained sections. Regions within sections
that had greater than 80% tumour material were selected
for needle-dissection. For tissue with a high tumour com-
ponent (>80%), whole tumour material was used for
DNA extraction. Genomic DNA was extracted using the
DNeasy kit (Qiagen, Hilden, Germany) according to the
manufacturer's protocol. Ovarian cancer samples with
typical TP53 mutations were selected to test sensitivity
and positive predictive value of the HRM methodology.
The breast tumour samples were collected from patientsPage 2 of 13
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Oxford, UK, according to the institute's ethical guidelines
(approval number C02.216). The tumours underwent
pathological review and genomic DNA was extracted from
fresh frozen tissue.
HRM assay conditions
The DNA samples were further diluted with PCR grade
water to a concentration of 0.5 ng/μL for use in PCR. Nor-
mal control DNA and cell line DNA was extracted using a
salting out method [29]. Primers were designed to flank
the coding regions and to be annealed at 60°C using
Primer Express software to calculate the "Tm" (Applied
Biosystems, Foster City, CA). The final optimal reaction
conditions were empirically determined. Final primer
sequences and the PCR annealing conditions are listed in
Table 1. A schematic representation of TP53 HRM assay
exons 5 to 8 is shown in Figure 1. The reaction mixture
used HotStarTaq (Qiagen, Hilden Germany) and con-
sisted of 2.5 ng of genomic DNA, 1× PCR buffer, 2.5 mM
MgCl2, 200 nM of each primer, 200 μM of dNTPs, 5 μM
of SYTO 9 (Invitrogen, Carlsbad, USA), 0.5 U of HotStar-
Taq polymerase and PCR grade water in a volume of 20
μL. All PCR reactions were performed in triplicate. PCR
cycling and HRM analysis was performed on the Rotor-
Gene™ 6000 (Corbett Research, Mortlake, New South
Wales, Australia). The PCR cycling conditions were as fol-
lows; one cycle of 95°C for 15 minutes; 50 cycles of 95°C
for 10 seconds, annealing conditions (see Table 1) for 5
seconds, 72°C for 20 seconds; one cycle of 95°C for 1 sec-
ond, 72°C for 90 seconds and a HRM step from 72 to
95°C rising at 0.1°C per second.
Sequencing methods
Ovarian tumour DNA samples
TP53 exons 5 to 8 were amplified using primers covering
the exons and exon-intron boundaries (see Table 2).
Amplification reactions (50 μl) contained 10 ng of DNA,
10 pmoles of each primer and 1.5 U of Amplitaq Gold
DNA polymerase (Applied Biosystems) according to man-
ufacturer's instructions. The amplifications were done
using a DNA Engine Tetrad, PTC-225 thermal cycler (Bio-
rad, Hercules, CA). PCR products were purified using the
NucleoFast 96 PCR plates from Macherey-Nagel using the
manufacturer's protocol. Purified PCR products were
sequenced using ABI Prism BigDye terminators v3.1
(Applied Biosystems) and an ABI 3100 genetic analyser
(Applied Biosystems). The results were analysed using
SeqScape v1.0 (Applied Biosystems). Sequencing reac-
tions were performed in forward and reverse directions.
All sequences were manually examined. All exons with a
mutation were re-amplified and re-sequenced in two
directions.
Breast tumour DNA samples
The HRM products were directly sequenced except that the
TP53_Exon5a_F and TP53_Exon5b_R primers (Table 1)
were used to amplify the entire TP53 exon 5 for sequenc-
ing using the HRM reaction mixture at the following con-
ditions; one cycle of 95°C for 15 minutes; 50 cycles of
95°C for 10 seconds, 65°C to 60°C touchdown (10 cycles
at 0.5°C per step) for 5 seconds, 72°C for 20 seconds. The
PCR products were column purified using the PCR-M
clean up kit (Viogene, Taipei, Taiwan) according to the
manufacturer's instructions. The PCR products were
eluted in a 50 μl volume, and 6 μl was treated with ExoS-
apIT (GE Healthcare, Buckinghamshire, England) accord-
ing to the manufacturer's instructions. The purified PCR
product was then used as template in cycle sequencing in
both forward and reverse directions with the Big Dye Ter-
minator v3.1 kit (Applied Biosystems). The reaction mix
consisted of 1× terminator premix, 1× sequencing buffer,
667 nM primer and 3.5 μl of cleaned template in a 15 μl
total volume. The reactions were run on a PTC-225 ther-
mal cycler according to the following protocol; one cycle
of 95°C for 1 minute; 25 cycles of 95°C for 10 seconds,
annealing temperature (64°C for full exon 5 and exon 8,
68°C for exons 6 and 7) for 30 seconds, 72°C for 3 min-
utes. The sequencing reactions were ethanol precipitated
and run on a 3100 Genetic Analyser. All sequences were
Table 1: TP53 HRM primers and PCR annealing temperature conditions
Exon Primer name Sequence Annealing conditions
5a TP53_Exon5a_F CAACTCTGTCTCCTTCCTCTTCCTAC 65–60°C touchdown 0.5°C/cycle for 10 cycles
TP53_Exon5a_R AGCCATGGCACGGACGCG
5b TP53_Exon5b_F CTCCTGCCCGGCACCCGC 65–60°C touchdown 0.5°C/cycle for 10 cycles
TP53_Exon5b_R CTAAGAGCAATCAGTGAGGAATCAGA
6 TP53_Exon6_F CAACCACCCTTAACCCCTCCT 68–58°C touchdown 1.0°C/cycle for 10 cycles
TP53_Exon6_R AGACGACAGGGCTGGTTGC
7 TP53_Exon7_F AGGCGCACTGGCCTCATC 68–58°C touchdown 1.0°C/cycle for 10 cycles
TP53_Exon7_R GAGGCTGGGGCACAGCA
8 TP53_Exon8_F GACCTGATTTCCTTACTGCCTCTTG 63.5–58.5°C touchdown 0.5°C/cycle for 10 cycles
TP53_Exon8_R AATCTGAGGCATAACTGCACCCTT
Underlined nucleotides are introduced sequencePage 3 of 13
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Corporation, Ann Arbor, MI).
HRM sensitivity testing
The cell lines used in this study are listed in Table 3. Cell
line DNA was mixed with wild-type DNA in dilutions of
50%, 25%, 10% and 5% to determine the sensitivity of
mutation detection of each amplicon. BT-20 and SKBR3
were used to test sensitivity of the 5a and 5b amplicons
respectively. T47D and OVCAR-3 was used to detect the
sensitivity of the exon 6 and 7 amplicons respectively.
RPMI8226 was used to assess the sensitivity of the exon 8
amplicon. The cell line dilutions were assessed by several
individuals in a blinded fashion where scoring depended
on being able to confidently differentiate the mutant con-
taining DNA dilutions from the wild-type DNA samples.
T47D was used in additional mixing experiments where
dilutions were made in wild-type DNA at 95%, 90% and
75% to assess the degree of heteroduplex formation at
higher mutant DNA proportions.
Results
HRM assay optimisation
The HRM amplicons for TP53 exons 5 to 8 are illustrated
in Figure 1 and the primer sequences listed in Table 1. Ini-
tially, amplicons for HRM analysis were designed to span
each of TP53 exons 5 to 8. We then tested the mutation
detection capability of each amplicon using a panel of
cancer cell lines (BT-20, SKBR3, T47D, KG-1, OVCAR-3,
SW480, MDA-MB231 RPMI8226) that were homozygous
or hemizygous for known TP53 mutations.
Figure 2 shows normalised plots and difference plots of
each cell line mutant compared to wild-type controls for
amplicons for exons 6, 7 and 8. In most cases, the differ-
ence between mutant and wild-type patterns was clear.
However, the T47D cell line (580C>T mutation, codon
194) had a melt profile that showed a subtle change in
melting behaviour (estimated Tm difference of 0.1°C)
compared to wild-type samples for exon 6 (Figure 2 panel
A). It must be borne in mind, however, that the difficulty
of detecting this change was due to only mutant sequence
being present and that most clinical samples would have
a mixture of normal cells with the resultant heterodu-
plexes considerably facilitating mutation detection.
Table 3: TP53 mutant cell lines used in study
Sample ID Mutation Protein 
change
Codon Exon
BT-20 394A>C K132Q 132 5
SKBR3 524G>A R175H 175 5
T47D 580C>T L194F 194 6
KG-1 673insATCTG frameshift 225 6
OVCAR-3 743G>A R248Q 248 7
SW480 818G>A R273H 273 8
MDA-MB231 839G>A R280K 280 8
RPMI8226 853G>A E285K 285 8
Schematic representation of amplicons for the TP53 HRM assayFigure 1
Schematic representation of amplicons for the TP53 HRM assay. Forward primers are in blue and reverse are in red. 
Exons 5 to 8 are represented by the green bars and the amplicon length and name are listed in the lower panels. Two ampli-
cons were designed to span TP53 exon 5.
Table 2: TP53 sequencing primers and annealing temperature 
conditions
Exon Primer 
name
Sequence Annealing 
temperature
5 TP53_5F CTCTGTCTCCTTCCTCTTCC 55°C
TP53_5R GCAATCAGTGAGGAATCAGAGG
6 TP53_6F AGATAGCGATGGTGAGCAGC 60°C
TP53_6R ACTGACAACCACCCTTAACC
7 TP53_7F CAGGTCTCCCCAAGGCGCAC 60°C
TP53_7R GCAAGCAGAGGCTGGGGCAC
8 TP53_8F GGAGTAGATGGAGCCTGGTT 58°C
TP53_8R GTGAATCTGAGGCATAACTGPage 4 of 13
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of the BT-20 cell line with the initial amplicon we
designed to span exon 5, although the 524G>A mutation
in codon 175 of the SKBR3 cell line was detectable (Figure
3, panel A). Examination of the TP53 exon 5 sequence
showed a GC rich region in the central region of the exon
(position 451 to 477 from start codon, CCCCCGCCCG-
GCACCCGCGTCCGCGCC) that resulted in several melt-
ing domains within the amplicon. We hypothesized that
the multiple melting domains were masking the presence
of the mutation in BT-20. Subsequently, we designed 2
overlapping amplicons for exon 5, named 5a and 5b. This
redesign relocated the GC rich regions to the end of each
fragment.
As the first fragment of exon 5 still had a very GC rich
domain at the 3' end and the second fragment still had a
GC rich domain at the 5' end, we adopted the novel strat-
egy of introducing sequence changes into the amplicons
via the primers to promote more homogeneous melting
characteristics as determined by the Poland program
which simulates the melting of double stranded DNA
[30]. Figure 3, panel B shows that the A to C mutation in
BT-20 is readily detectable using the redesigned 5a ampli-
con.
Sensitivity testing results using cell lines
We estimated the sensitivity of HRM for each amplicon
with dilutions of TP53 mutant cell line DNA in wild-type
DNA for the cell lines BT-20, SKBR3, T47D, OVCAR-3 and
RPMI8226. Dilutions were made at 50%, 25%, 10% and
5% mutant DNA and the results were assessed by several
individuals in a blinded fashion. Cell line DNA down to
5% was detected for each TP53 amplicon. Figure 4 shows
TP53 cell line mutations detected by HRMFigure 2
TP53 cell line mutations detected by HRM. Cell line mutant samples are in red and wild-type samples are in blue. Nor-
malised plots are on the left and the corresponding difference plots are on the right. Panel A - T47D 580C>T mutation in exon 
6. Panel B - OVCAR-3 743G>A mutation in exon 7. Panel C - MDA-MB231 839G>A, SW480 818G>A, RPMI8226 853G>A 
mutations in exon 8.  Page 5 of 13
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amplicon.
The T47D cell line was used to test the exon 6 amplicon.
We could not readily distinguish the 100% T47D melt
profile from the wild-type melt profiles. It appears that the
minimal difference in melting behaviour between T47D
and wild-type combined with spread of the wild-type melt
profiles, contributed to the difficulty in scoring (Figure 4,
panel C). Mixing experiments with T47D showed that at
dilutions of 95%, 90% and 75%, there was sufficient het-
eroduplex formation to allow ready detection of the
mutant sequence [see Additional file 1].
Screening TP53 exons 5 to 8 in the ovarian tumour panel
We screened 20 ovarian tumour biopsy samples that had
previously been sequenced for mutations in TP53 exons 5
to 8. Analysis of the HRM data was done blinded to the
sequencing results. We observed the presence of aberrant
melt profiles in all 20 samples. The majority of the melt
profiles were clearly distinguishable on difference plots
from wild-type by amplitude and/or by shape. Figure 5
shows examples of aberrant melt profiles for each ampli-
con.
Table 4 lists all the HRM and sequencing results for each
of the ovarian tumour DNA samples. The sequencing
results showed that there were TP53 mutations in all 20
samples (unknown to the HRM scorers at the time of the
blinded analysis) and aberrant profiles by HRM were
observed for each sample in the correct exons. There were
18 mutations that occurred with the coding region of
TP53 and two changes present in the intronic sequence,
one in intron 4–5 and the other in intron 5–6.
Samples that were mutation-negative for a particular exon
were internal negative controls and all mutations detected
by sequencing were detected by HRM. Each mutation was
correctly identified in each exon giving 100% sensitivity
for HRM within this sample set. We were uncertain about
the mutation status of 2 samples in exon 6 and these
TP53 exon 5 amplicon redesign allowed detection of the BT-20 645A>C mutationFigur  3
TP53 exon 5 amplicon redesign allowed detection of the BT-20 645A>C mutation.  Cell line mutant samples are in 
red and wild-type samples are in blue. All plots shown in this figure are difference plots. Panel A; BT-20 394A>C and SKBR3 
524G>A mutations with the original amplicon designed for exon 5. Panel B; BT-20 394A>C mutation is now detectable with 
the 5a amplicon. Panel C; SKBR3 524G>A mutation with the 5b amplicon.  Page 6 of 13
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predictive value of 91% for HRM within this sample set.
Figure 6 shows a normalised plot and a difference plot of
TP53 exon 6 for patient 22. This sample had a subtle
change in melting behaviour as seen with the slightly
altered shape of the melt profile when compared to wild-
type samples (Figure 6, panel A). The change in shape is
more clearly seen with the difference plot with a promi-
nent early melt, characteristic of heteroduplexes (Figure 6,
panel B). The melt profile for patient 22 was close to the
range of what would be classified as normal as the Tm dif-
ference was between it and the wild-type samples was
minimal. Patient 22 had a 578A>G mutation identified by
sequencing.
Screening TP53 exons 5 to 8 in the breast tumour panel
We screened 20 breast tumour biopsy samples with
unknown TP53 mutation status using HRM. We observed
the presence of aberrant melt profiles in 7 of the samples.
No mutations were detected by sequencing in samples
scored as wild-type by HRM. The majority of the melt pro-
files were clearly distinguishable on difference plots from
wild-type by amplitude and/or by shape. Figure 7 shows
examples of aberrant melt profiles for TP53 exon 7 for
samples B4 and B9. The low peak height in the sequencing
trace for the 711G>A mutation in sample B4 was reflective
of the melt profile in HRM, where the shift was of a lower
magnitude than sample B9. The data for samples B4 and
B14 (Figure 8) indicated that mutations detectable by
HRM were at the lower limit of detection by dideoxy
sequencing.
Dilution of cell line mutant DNA to test sensitivity of TP53 HRM ampliconsFigure 4
Dilution of cell line mutant DNA to test sensitivity of TP53 HRM amplicons. Wild-type samples are in blue and all 
plots shown are difference plots. Panel A: BT-20 dilution series. Panel B; SKBR3 dilution series. Panel C; T47D dilution series. 
Panel D; OVCAR-3 dilution series. Panel E; RPMI8226 dilution series.Page 7 of 13
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breast tumour DNA samples. The sequencing results con-
firmed that there were TP53 mutations in all samples that
had aberrant curves by HRM. There were 5 missense muta-
tions and 2 null mutations.
Discussion
There have been numerous methods employed to detect
TP53 mutations, each with its particular advantages and
disadvantages. Scanning methodologies such as SSCP,
gradient gel electrophoresis and denaturing high perform-
ance liquid chromatography (DHPLC) are advantageous
because they significantly reduce the amount of sequenc-
ing that ultimately needs to be performed [31-36], stream-
lining the mutation detection process and making it more
cost effective. The high resolution melting methodology
presented here has the additional advantages over other
scanning methodologies of increased simplicity and rapid
turn-around-time, because it is performed directly after
PCR amplification in the same tube. We chose exons 5 to
Example of aberrant melt profiles observed for ovarian tumour samplesFigure 5
Example of aberrant melt profiles observed for ovarian tumour samples. Wild-type control samples are in blue. 
Wild-type patient samples are in green and mutant patient samples are in red. Panel A; mutation in patient 33 in exon 5 with 
amplicon 5a. Panel B; mutations in patients 9, 13 and 14 in exon 5 with amplicon 5b. Panel C; mutation in patient 4 in exon 6. 
Panel D; mutations in patients 21 and 28 in exon 7. Panel E; mutations in patients 6, 15 and 17 in exon 8.Page 8 of 13
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regions [10].
Although the sensitivity is likely to be dependent on the
particular mutation, the cell line testing results indicate a
high sensitivity for HRM down to 5% mutant sequence.
The sensitivity testing results also indicate that the overall
variation of biological replicates of wild-type melt profiles
will affect the ability to discriminate mutant samples from
wild-type, which will ultimately affect the sensitivity of
the technique.
Samples with pure mutant DNA could pose a problem for
detection with HRM. For example, in cell lines containing
only a mutant allele due to LOH of the remaining WT
allele, in some cases (e.g. T47D) the resultant PCR prod-
uct has minimal temperature difference compared to that
amplified from wild-type DNA. However, this is a theoret-
ical rather than a practical consideration as a proportion
of wild-type DNA will be present in a tumour biopsy even
with microdissection of the tissue specimen. Indeed, the
addition of a small amount of wild-type DNA (5%) to
T47D caused a sufficient heteroduplex effect to facilitate
detection by HRM [see Additional file 1]. Addition of 5–
10% wild type DNA should be considered for samples are
known to be extremely pure, such as those that have been
purified by laser-capture microdissection.
HRM analysis requires careful attention to the design of
the amplicons as mutation detection is easier when there
is a single melting domain. This is exemplified by exon 5
in which the 394A>C mutation in the 5' end of the exon
was not initially observed under the conditions used. This
was even the case when the cell line was diluted with nor-
mal DNA to create a heterozygous mutation (data not
shown). We found that separating the amplicon into 2
domains allowed the detection of this mutation and all
other mutations tested. We furthermore manipulated the
primers, which encompassed a GC region between the 2
domains by introducing sequence changes into the prim-
ers, which promoted greater homogeneity in the melting
behavior of the amplicon.
The ovarian tumour DNA panel was used to assess the
sensitivity and positive predictive value of HRM for TP53
exons 5 to 8. The samples chosen were preselected for
mutations in these exons but otherwise we performed a
blinded analysis. There were a number of samples that
had large shifts from the melt profiles of wild-type sam-
ples whereas others had changes that were more subtle.
The aberrant curve produced for sample 22 in exon 6
appeared closer to a wild-type sample than a mutant
because the profile existed within the spread for samples
resembling wild type. However, the sample was classified
as having an aberrant melt profile because of its conspic-
uously different shape, the earlier melting that is charac-
teristic of heteroduplex formation, and because replicates
Table 4: Summary of HRM and sequencing results for the AOCS ovarian tumour panel
Sample ID HRM results Sequencing results
Exon 5 5a Exon 5 5b Exon 6 Exon 7 Exon 8 Nomencla
ture
Protein 
change
Zygosity Exon
4 wt wt MUT wt wt 574C>T Q192Stop het 6
6 wt wt wt wt MUT 818G>A R273H het 8
9 wt MUT wt wt wt 503A>C H168P het 5
11 wt wt wt MUT wt 734G>A G245D het 7
13 wt MUT wt wt wt 524G>A R175H hom 5
14 wt MUT wt wt wt 487T>C Y163H het 5
15 wt wt ? wt MUT 824G>A C275Y het 8
16 wt wt wt MUT wt 743G>A R248Q het 7
17 wt wt wt wt MUT 871C>T R273C het 8
19 wt wt wt MUT wt 713G>A C238Y het 7
21 wt wt ? MUT wt 734G>T G245V - 7
22 Wt wt MUT wt wt 578A>G H193R - 6
25 Wt MUT wt wt wt 493C>T Q165Stop hom 5
27 Wt wt MUT wt wt IVS5-2A>C - - intron 5
28 Wt wt wt MUT wt 770T>C L257P het 7
33 MUT wt wt wt wt IVS4-1G>T - - intron 4
35 Wt wt wt wt MUT 818G>A R273H het 8
45 Wt MUT wt wt wt 499C>T Q167Stop het 5
48 Wt wt wt MUT wt 772G>A E258K het 7
59 Wt MUT wt wt wt 488A>G Y163C het 5
wt - wild type, MUT - Mutant, het – heterozygous, hom – homozygous, ? – unable to scorePage 9 of 13
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data showed that sample 22 had an A to G change at base
578. In this sample set, the HRM methodology had 100%
sensitivity and 91% positive predictive value.
The screening of 20 breast tumour DNA samples with an
unknown TP53 mutation status followed by sequencing
of all the samples allowed us to further assess the sensitiv-
ity and positive predictive value of the methodology.
Seven samples had aberrant melt profiles indicating the
presence of a mutation and the sequencing results con-
firmed the presence of the mutations (see Table 5). In
addition, there were no mutations detected by sequencing
in samples scored as wild-type by HRM. This gave 100%
sensitivity and 100% positive predictive value for HRM
for the breast tumour sample set. Larger studies are
needed to further assess the sensitivity and positive pre-
dictive value of the current methodology.
In the breast tumour sample set, sample B14 was interest-
ing as it was scored as a query by HRM and subsequent
sequencing showed the presence of a 531_533delC muta-
tion that was present at a low percentage (Figure 8). Data
from other HRM studies (our unpublished results) indi-
cate that deletions/insertion of a single base do not have
the same magnitude of change in melt profile compared
to that of a heterozygous SNP. Another sample, B4 was
interesting as the HRM data indicated a clear mutation but
the sequencing data showed the mutation at the lower
limit of detection. These cases reflected the lower propor-
tion of tumour in some of the samples as there was no
enrichment of the tumour component before DNA extrac-
tion.
One of the major advantages of HRM is for the detection
of somatic mutations in genes that can have alterations at
HRM difference plot and sequencing data for breast tumour samples or TP53 exo  7Figur  7
HRM difference plot and sequencing data for breast 
tumour samples for TP53 exon 7. Panel A; Difference 
plot of breast tumour samples for TP53 exon 7. Wild-type 
control samples are in blue, wild-type patient samples are in 
green, the cell line OVCAR-3 is in red and samples B4 and B9 
are in orange. Panel B; Sequencing traces for wild-type, B4 
and B9.
Subtle change in melt profile observed for patient 22 in TP53 exon 6Figure 6
Subtle change in melt profile observed for patient 22 
in TP53 exon 6. Wild-type control samples are in blue. 
Wild-type patient samples are in green and mutant patient 
samples are in red. Panel A; normalised plot of patient 22 
compared to wild-type controls and wild-type ovarian 
tumour samples in exon 6. Panel B; difference plot of patient 
22 compared to wild-type controls and wild-type ovarian 
tumour samples.Page 10 of 13
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HRM difference plot and sequencing data for breast tumour samples for TP53 exon 5, 5b ampliconFigure 8
HRM difference plot and sequencing data for breast tumour samples for TP53 exon 5, 5b amplicon. Panel A; Dif-
ference plot of breast tumour samples for TP53 exon 5, amplicon 5b. Wild-type control samples are in blue, wild-type patient 
samples are in green, the cell line SKBR3 is in red, sample B6 is in orange and sample B14 is in pink. Panel B; Sequencing traces 
for wild-type, B6 and B14.
Table 5: Summary of HRM and sequencing results for the breast tumour panel
Sample 
ID
HRM results Sequencing results
Exon 5 5a Exon 5 5b Exon 6 Exon 7 Exon 8 Nomenclature Protein change Exon
B1 wt wt wt wt wt NA NA NA
B2 wt wt wt wt wt NA NA NA
B3 wt MUT wt wt wt 524G>A R175H 5
B4 wt wt wt MUT wt 711G>A M237I 7
B5 wt wt wt wt wt NA NA NA
B6 wt MUT wt wt wt 527G>T C176F 5
B7 wt wt wt wt wt NA NA NA
B8 wt wt wt wt wt NA NA NA
B9 wt wt wt MUT wt 711G>A M237I 7
B10 wt wt wt wt wt NA NA NA
B11 wt wt wt wt wt NA NA NA
B12 wt wt wt wt wt NA NA NA
B13 wt wt wt wt wt NA NA NA
B14 wt ? wt wt wt 531_533delC frame shift, H178fs 5
B15 wt wt wt wt wt NA NA NA
B16 wt wt MUT wt wt 614A>T Y205F 6
B17 wt wt wt wt wt NA NA NA
B18 wt wt wt wt wt NA NA NA
B19 wt MUT wt wt wt 513_515delGinsAT frame shift, V172fs 5
B20 wt wt wt wt wt NA NA NA
wt - wild-type, MUT – Mutant, het – heterozygous, hom – homozygous, ? – unable to score, NA – not applicable
BMC Cancer 2007, 7:168 http://www.biomedcentral.com/1471-2407/7/168different positions in the coding sequence. Because in
addition to pathogenic mutations, HRM will detect SNPs,
silent mutations and intronic variation of unknown sig-
nificance, and may have an intrinsic false positive rate,
any aberrant melt curves should be validated by sequenc-
ing.
Conclusion
This study validates the use of HRM as a method to scan
for somatic mutations in TP53. The method is sensitive,
rapid and cost effective and will markedly reduce the
amount of sequencing required in mutational studies of
TP53 and thereby the cost required for these studies.
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